The skeleton: Endocrine regulator of phosphate homeostasis (original) (raw)

• Mirams M, Robinson BG, Mason RS, Nelson AE: Bone as a source of FGF23: regulation by phosphate? Bone 2004, **35:**1192–1199.
  Article PubMed CAS Google Scholar
• Yoshiko Y, Wang H, Minamizaki T, et al.: Mineralized tissue cells are a principal source of FGF23. Bone 2007, **40:**1565–1573.
  Article PubMed CAS Google Scholar
• Kato K, Jeanneau C, Tarp MA, et al.: Polypeptide GalNActransferase T3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosylation. J Biol Chem 2006, **281:**18370–18377.
  Article PubMed CAS Google Scholar
• Urakawa I, Yamazaki Y, Shimada T, et al.: Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006, **444:**770–774.
  Article PubMed CAS Google Scholar
• Kuro-o M, Matsumura Y, Aizawa H, et al.: Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997, **390:**45–51.
  Article PubMed CAS Google Scholar
• Shimada T, Kakitani M, Yamazaki Y, et al.: Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004, **113:**561–568.
  PubMed CAS Google Scholar
• Tohyama O, Imura A, Iwano A, et al.: Klotho is a novel beta-glucuronidase capable of hydrolyzing steroid betaglucuronides. J Biol Chem 2004, **279:**9777–9784.
  Article PubMed CAS Google Scholar
• Matsumura Y, Aizawa H, Shiraki-Iida T, et al.: Identification of the human Klotho gene and its two transcripts encoding membrane and secreted Klotho protein. Biochem Biophys Res Commun 1998, **242:**626–630.
  Article PubMed CAS Google Scholar
• Bacic D, Wagner CA, Hernando N, et al.: Novel aspects in regulated expression of the renal type IIa Na/Pi-cotransporter. Kidney Int Suppl 2004, **(91):**S5–S12.
• Miyamoto K, Ito M, Kuwahata M, et al.: Inhibition of intestinal sodium-dependent inorganic phosphate transport by fibroblast growth factor 23. Ther Apher Dial 2005, **9:**331–335.
  Article PubMed CAS Google Scholar
• Shimada T, Yamazaki Y, Takahashi M, et al.: Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol 2005, **289:**F1088–F1095.
  Article PubMed CAS Google Scholar
• Perwad F, Zhang MY, Tenenhouse HS, Portale AA: Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. Am J Physiol Renal Physiol 2007, **293:**F1577–F1583.
  Article PubMed CAS Google Scholar
• Kolek OI, Hines ER, Jones MD, et al.: 1alpha,25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am J Physiol Gastrointest Liver Physiol 2005, **289:**G1036–G1042.
  Article PubMed CAS Google Scholar
• Saito H, Maeda A, Ohtomo S, et al.: Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 2005, **280:**2543–2549.
  Article PubMed CAS Google Scholar
• Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, et al.: The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007, **117:**4003–4008.
  PubMed CAS Google Scholar
• Shimada T, Mizutani S, Muto T, et al.: Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 2001, **98:**6500–6505.
  Article PubMed CAS Google Scholar
• Shimada T, Urakawa I, Yamazaki Y, et al.: FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun 2004, **314:**409–414.
  Article PubMed CAS Google Scholar
• Jan De Beur SM, Finnegan RB, Vassiliadis J, et al.: Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism. J Bone Miner Res 2002, **17:**1102–1110.
  Article CAS Google Scholar
• Bowe AE, Finnegan R, Jan de Beur SM, et al.: FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun 2001, **284:**977–981.
  Article PubMed CAS Google Scholar
• White KE, Jonsson KB, Carn G, et al.: The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab 2001, **86:**497–500.
  Article PubMed CAS Google Scholar
• Jonsson KB, Zahradnik R, Larsson T, et al.: Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 2003, **348:**1656–1663.
  Article PubMed CAS Google Scholar
• White KE, Larsson TE, Econs MJ: The roles of specific genes implicated as circulating factors involved in normal and disordered phosphate homeostasis: frizzled related protein-4, matrix extracellular phosphoglycoprotein, and fibroblast growth factor 23. Endocr Rev 2006, **27:**221–241.
  Article PubMed CAS Google Scholar
• ADHR Consortium: Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000, **26:**345–348.
  Article CAS Google Scholar
• Bai XY, Miao D, Goltzman D, Karaplis AC: The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem 2003, **278:**9843–9849.
  Article PubMed CAS Google Scholar
• Shimada T, Muto T, Urakawa I, et al.: Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 2002, **143:**3179–3182.
  Article PubMed CAS Google Scholar
• White KE, Carn G, Lorenz-Depiereux B, et al.: Autosomaldominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 2001, **60:**2079–2086.
  Article PubMed CAS Google Scholar
• A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium [no authors listed]. Nat Genet 1995, **11:**130–136.
• Liu S, Guo R, Simpson LG, et al.: Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 2003, **278:**37419–37426.
  Article PubMed CAS Google Scholar
• Benet-Pages A, Lorenz-Depiereux B, Zischka H, et al.: FGF23 is processed by proprotein convertases but not by PHEX. Bone 2004, **35:**455–462.
  Article PubMed CAS Google Scholar
• Feng JQ, Ward LM, Liu S, et al.: Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 2006, **38:**1310–1315.
  Article PubMed CAS Google Scholar
• Tartaix PH, Doulaverakis M, George A, et al.: In vitro effects of dentin matrix protein-1 on hydroxyapatite formation provide insights into in vivo functions. J Biol Chem 2004, **279:**18115–18120.
  Article PubMed CAS Google Scholar
• Feng JQ, Huang H, Lu Y, et al.: The Dentin matrix protein 1 (Dmp1) is specifically expressed in mineralized, but not soft, tissues during development. J Dent Res 2003, **82:**776–780.
  Article PubMed CAS Google Scholar
• Riminucci M, Collins MT, Fedarko NS, et al.: FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 2003, **112:**683–692.
  PubMed CAS Google Scholar
• White KE, Cabral JM, Davis SI, et al.: Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation. Am J Hum Genet 2005, **76:**361–367.
  Article PubMed CAS Google Scholar
• Brownstein CA, Adler F, Nelson-Williams C, et al.: A translocation causing increased alpha-klotho level results in hypophosphatemic rickets and hyperparathyroidism. Proc Natl Acad Sci U S A 2008, **105:**3455–3460.
  Article PubMed CAS Google Scholar
• Tieder M, Modai D, Samuel R, et al.: Hereditary hypophosphatemic rickets with hypercalciuria. N Engl J Med 1985, **312:**611–617.
  Article PubMed CAS Google Scholar
• Ichikawa S, Sorenson AH, Imel EA, et al.: Intronic deletions in the SLC34A3 gene cause hereditary hypophosphatemic rickets with hypercalciuria. J Clin Endocrinol Metab 2006, **91:**4022–4027.
  Article PubMed CAS Google Scholar
• Lorenz-Depiereux B, Bastepe M, Benet-Pages A, et al.: DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet 2006, **38:**1248–1250.
  Article PubMed CAS Google Scholar
• Bergwitz C, Roslin NM, Tieder M, et al.: SLC34A3 mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria predict a key role for the sodium-phosphate cotransporter NaPi-IIc in maintaining phosphate homeostasis. Am J Hum Genet 2006, **78:**179–192.
  Article PubMed CAS Google Scholar
• Prie D, Huart V, Bakouh N, et al.: Nephrolithiasis and osteoporosis associated with hypophosphatemia caused by mutations in the type 2a sodium-phosphate cotransporter. N Engl J Med 2002, **347:**983–991.
  Article PubMed CAS Google Scholar
• Karim Z, Gérard B, Bakouh N, et al.: NHERF1 mutations and responsiveness of renal parathyroid hormone. N Engl J Med 2008, **359:**1128–1135.
  Article PubMed CAS Google Scholar
• Sitara D, Razzaque MS, Hesse M, et al.: Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol 2004, **23:**421–432.
  Article PubMed CAS Google Scholar
• Topaz O, Shurman DL, Bergman R, et al.: Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet 2004, **36:**579–581.
  Article PubMed CAS Google Scholar
• Ichikawa S, Lyles KW, Econs MJ: A novel GALNT3 mutation in a pseudoautosomal dominant form of tumoral calcinosis: evidence that the disorder is autosomal recessive. J Clin Endocrinol Metab 2005, **90:**2420–2423.
  Article PubMed CAS Google Scholar
• Chefetz I, Heller R, Galli-Tsinopoulou A, et al.: A novel homozygous missense mutation in FGF23 causes Familial Tumoral Calcinosis associated with disseminated visceral calcification. Hum Genet 2005, **118:**261–266.
  Article PubMed CAS Google Scholar
• Benet-Pages A, Orlik P, Strom TM, Lorenz-Depiereux B: An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 2005, **14:**385–390.
  Article PubMed CAS Google Scholar
• Araya K, Fukumoto S, Backenroth R, et al.: A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. J Clin Endocrinol Metab 2005, **90:**5523–5527.
  Article PubMed CAS Google Scholar
• Ichikawa S, Guigonis V, Imel EA, et al.: Novel GALNT3 mutations causing hyperostosis-hyperphosphatemia syndrome result in low intact fibroblast growth factor 23 concentrations. J Clin Endocrinol Metab 2007, **92:**1943–1947.
  Article PubMed CAS Google Scholar
• Kurosu H, Ogawa Y, Miyoshi M, et al.: Regulation of fibroblast growth factor-23 signaling by Klotho. J Biol Chem 2006, **281:**6120–6123.
  Article PubMed CAS Google Scholar
• Ichikawa S, Imel EA, Kreiter ML, et al.: A homozygous missense mutation in human Klotho causes severe tumoral calcinosis. J Clin Invest 2007, **117:**2684–2691.
  Article PubMed CAS Google Scholar